Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes in preterm, high-risk and healthy-term infants, Quebec, Canada

2025-07-27 infectious diseases Title + abstract only

Show abstract

BackgroundDuring the 2024-25 season, a universal infant nirsevimab program was publicly funded in Quebec, Canada. We estimated effectiveness, number-needed-to-immunize (NNI) and impact against severe respiratory syncytial virus (RSV) outcomes. MethodsWe conducted a test-negative study among nirsevimab-eligible children RSV-tested during ER consultation or hospitalization between October 1st, 2024 and March 3st, 2025. Eligible children were healthy-term and born during the RSV season (at-birth g...

Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes in preterm, high-risk and healthy-term infants, Quebec, Canada

Predicted journal destinations